title: Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
abstract: Dietary management of hyperphosphatemia and hyperparathyroidism have long been important elements in the clinical management of CKD stage 4 and 5 for the prevention of mineral bone disease. The rationale for phosphate lowering has been further justified, given the accumulating data to support the association of phosphate with vascular damage, in this population who are at high risk of cardiovascular (CV) death. Phosphate is a novel CV risk factor in both CKD and in the general population, and a growing body of literature suggests that high normal serum phosphate may be a risk factor for progression of CKD. Few studies have examined hard outcomes after phosphate lowering. Nonetheless, given the balance of data both in cell, animal and human studies, the use of phosphate lowering strategies at earlier stages of CKD, perhaps even prior to serum phosphate level rising, may well be justified. This review will discuss the complications associated with higher serum phosphate, the potential benefits of early phosphate intervention, practical considerations of low phosphate diets and novel strategies for evaluating these strategies in clinical practice.
authors.affiliation: University of British Columbia, St. Paul's Hospital, Vancouver, Canada. msigrist@providencehealth.bc.ca
authors.forename: M K
authors.initials: MK
authors.lastname: Sigrist
authors.forename: G
authors.initials: G
authors.lastname: Chiarelli
authors.forename: L
authors.initials: L
authors.lastname: Lim
authors.forename: A
authors.initials: A
authors.lastname: Levin
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D002614:Chelating Agents / Q000627:therapeutic use; D018450:Disease Progression; D055317:Evidence-Based Practice; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000502:physiology; D005503:Food Additives / Q000737:chemistry; D019983:Guideline Adherence; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D054559:Hyperphosphatemia / Q000178:diet therapy* / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications*; D008612:Menu Planning; D009398:Nephrology / Q000379:methods; D009753:Nutritive Value; D010758:Phosphorus / Q000032:analysis / Q000097:blood / Q000652:urine; D016226:Phosphorus, Dietary / Q000009:adverse effects* / Q000032:analysis; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D002614:Chelating Agents; D005503:Food Additives; D016226:Phosphorus, Dietary; D010758:Phosphorus; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23